Literature DB >> 7689440

Fluoroquinolones and surgical prophylaxis.

P Dellamonica1, E Bernard.   

Abstract

The objective of surgical prophylaxis is to prevent wound infections associated with surgery. The rates of wound infections vary according to the procedure: less than 3 infections per 100 for clean procedures; up to 4 per 100 for clean-contaminated procedures; and up to 9 per 100 for contaminated procedures. Surgical antimicrobial prophylaxis has been shown in many randomised clinical trials to reduce the incidence of postoperative wound infections. Such prophylaxis is actually recommended in many clean-contaminated and some clean procedures. Because of their antimicrobial, pharmacokinetic, and antiadhesive properties, the fluoroquinolones have been recently proposed as prophylactic agents. Fluoroquinolones have proved to be useful in surgical prophylaxis and clinical trials have been performed in orthopaedic, cardiovascular, biliary, colorectal and urological surgery. According to the surgical procedure, fluoroquinolones were compared either with the standard antimicrobial regimen or with placebo. Different regimens of fluoroquinolones were also compared. Generally, fluoroquinolones have been demonstrated to be as effective as the reference prophylactic agent. In transurethral surgery, fewer postoperative wound infections were reported in the treated group than in the placebo group. In most studies, single dose prophylaxis was as effective as a multiple dose regimen. It is important to note that strict methodology was limited to a few clinical trials. In most of the studies, patients were not randomised in a double-blind fashion and small patient numbers often prevented the formation of satisfactory conclusions. Further trials are needed to define the role of the fluoroquinolones in surgical prophylaxis. It will be important to evaluate not only the efficacy but also the cost-benefit of perioperative prophylaxis with the fluoroquinolones. Clinical trials are also required in other high risk clean procedures such as neurosurgery involving shunts and ocular surgery. However, the risks related to the extensive use of fluoroquinolones in surgical prophylaxis must be considered, including the development and dissemination of resistant pathogens and the occurrence of adverse effects. In the future, surgical prophylaxis with prosthetic devices coated with fluoroquinolones should be considered.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689440     DOI: 10.2165/00003495-199300453-00018

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  33 in total

1.  Antibiotic prophylaxis of late bacteremic vascular graft infection in a dog model.

Authors:  O Goëau-Brissonnière; C Leport; C Lebrault; F J Renier; F Bacourt; J L Vildé; J C Péchère
Journal:  Ann Vasc Surg       Date:  1990-11       Impact factor: 1.466

Review 2.  Antibiotic prophylaxis in clean surgery: peripheral vascular surgery, noncardiovascular thoracic surgery, herniorrhaphy, and mastectomy.

Authors:  C C Hopkins
Journal:  Rev Infect Dis       Date:  1991 Sep-Oct

Review 3.  Tissue penetration of the new quinolones in humans.

Authors:  D N Gerding; J A Hitt
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

4.  Ciprofloxacin for single shot prophylaxis during cholecystectomy.

Authors:  J Kögler; E Hancke; G Marklein; H J Somner; A Schmitz; A Fuhrman
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

5.  Oral ciprofloxacin as prophylaxis in transurethral resection of the prostate.

Authors:  D A Murdoch; D F Badenoch; E R Gatchalian
Journal:  Br J Urol       Date:  1987-08

6.  Penetration of ciprofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans.

Authors:  P M Mertes; P Voiriot; C Dopff; H Scholl; M Clavey; J P Villemot; P Canton; J B Dureux
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

7.  Simple methods for direct antibiotic protection of synthetic vascular grafts.

Authors:  J V White; A I Benvenisty; K Reemtsma; A B Voorhees; C L Fox; S Modak; R Nowygrod
Journal:  J Vasc Surg       Date:  1984-03       Impact factor: 4.268

8.  The comparative in-vitro activity of eight newer quinolones and nalidixic acid.

Authors:  A King; I Phillips
Journal:  J Antimicrob Chemother       Date:  1986-11       Impact factor: 5.790

9.  Antibiotic prophylaxis in vascular surgery.

Authors:  A B Kaiser; K R Clayson; J L Mulherin; A C Roach; T R Allen; W H Edwards; W A Dale
Journal:  Ann Surg       Date:  1978-09       Impact factor: 12.969

10.  Comparison of intravenous ciprofloxacin and intravenous cefotaxime for antimicrobial prophylaxis in transurethral surgery.

Authors:  C E Cox
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

View more
  3 in total

Review 1.  The appropriate use of quinolones.

Authors:  A Percival
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 2.  Methicillin-resistant staphylococci in clean surgery. Is there a role for prophylaxis?

Authors:  E Mini; S Nobili; P Periti
Journal:  Drugs       Date:  1997       Impact factor: 9.546

3.  Pharmacokinetics and tissue distribution of intravenous ofloxacin for antibiotic prophylaxis in biliary surgery.

Authors:  A R Gascón; E Campo; R M Hernández; B Calvo; J Errasti; J L Pedraz
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.